EU/3/08/549

Table of contents

About

On 3 June 2008, orphan designation (EU/3/08/549) was granted by the European Commission to MolMed S.p.A, Italy, for NGR-human Tumour Necrosis Factor for the treatment of malignant mesothelioma.

Key facts

Active substance
NGR-human tumour necrosis factor
Disease / condition
Treatment of malignant mesothelioma
Date of first decision
03/06/2008
Outcome
Positive
EU designation number
EU/3/08/549

Sponsor's contact details

MolMed S.p.A.
Via Olgettina 58
20132 Milan
Italy
Telephone: +39 02 212 771
Telefax: +39 02 212 77 220
E-mail: info@molmed.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

Related content

How useful was this page?

Add your rating